Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

• Piper Sandler 36th Annual Healthcare Conference
  Date: Tuesday, December 3, 2024
  Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT
  Location: New York City
  

• 7th Annual Evercore HealthCONx Conference
  Date: Wednesday, December 4, 2024
  Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT
  Location: Coral Gables, Florida

Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241126889211/en/

Charles Liles
[email protected]
(626) 737-8118

Source: Xencor, Inc.

You May Also Be Interested In

• e.l.f. Cosmetics Answers Community Demand with the Return of Pickle-Inspired Glow Reviver Melting Lip Balms
• The Bank of Lithuania’s Financial Market Supervision Committee has granted Modestas Sutkaitis permission to serve as a member of the Management Board of UAB Urbo bankas
• Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies